{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T09:54:13Z","timestamp":1792144453710,"version":"4.4.0"},"reference-count":89,"publisher":"American Diabetes Association","issue":"12","license":[{"start":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T00:00:00Z","timestamp":1664755200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.diabetesjournals.org\/journals\/pages\/license"}],"content-domain":{"domain":["diabetesjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12,1]]},"abstract":"<jats:p>People with diabetes and chronic kidney disease (CKD) are at high risk for kidney failure, atherosclerotic cardiovascular disease, heart failure, and premature mortality. Recent clinical trials support new approaches to treat diabetes and CKD. The 2022 American Diabetes Association (ADA) Standards of Medical Care in Diabetes and the Kidney Disease: Improving Global Outcomes (KDIGO) 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease each provide evidence-based recommendations for management. A joint group of ADA and KDIGO representatives reviewed and developed a series of consensus statements to guide clinical care from the ADA and KDIGO guidelines. The published guidelines are aligned in the areas of CKD screening and diagnosis, glycemia monitoring, lifestyle therapies, treatment goals, and pharmacologic management. Recommendations include comprehensive care in which pharmacotherapy that is proven to improve kidney and cardiovascular outcomes is layered on a foundation of healthy lifestyle. Consensus statements provide specific guidance on use of renin-angiotensin system inhibitors, metformin, sodium\u2013glucose cotransporter 2 inhibitors, glucagon-like peptide 1 receptor agonists, and a nonsteroidal mineralocorticoid receptor antagonist. These areas of consensus provide clear direction for implementation of care to improve clinical outcomes of people with diabetes and CKD.<\/jats:p>","DOI":"10.2337\/dci22-0027","type":"journal-article","created":{"date-parts":[[2022,10,3]],"date-time":"2022-10-03T06:00:36Z","timestamp":1664776836000},"page":"3075-3090","update-policy":"https:\/\/doi.org\/10.2337\/ada-journal-policies","source":"Crossref","is-referenced-by-count":848,"title":["Diabetes Management in Chronic Kidney Disease: A Consensus Report by the American Diabetes Association (ADA) and Kidney Disease: Improving Global Outcomes (KDIGO)"],"prefix":"10.2337","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1571-7592","authenticated-orcid":false,"given":"Ian H.","family":"de Boer","sequence":"first","affiliation":[{"name":"1Kidney Research Institute, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamlesh","family":"Khunti","sequence":"additional","affiliation":[{"name":"2Diabetes Research Centre, University of Leicester, Leicester, U.K."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami","family":"Sadusky","sequence":"additional","affiliation":[{"name":"3University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine R.","family":"Tuttle","sequence":"additional","affiliation":[{"name":"4University of Washington, Spokane, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J.","family":"Neumiller","sequence":"additional","affiliation":[{"name":"5College of Pharmacy and Pharmaceutical Sciences, Washington State University, Spokane, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Connie M.","family":"Rhee","sequence":"additional","affiliation":[{"name":"6University of California, Irvine, Orange, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sylvia E.","family":"Rosas","sequence":"additional","affiliation":[{"name":"7Joslin Diabetes Center and Harvard Medical School, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Rossing","sequence":"additional","affiliation":[{"name":"8Steno Diabetes Center Copenhagen, Copenhagen, Demark"},{"name":"9University of Copenhagen, Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Bakris","sequence":"additional","affiliation":[{"name":"10University of Chicago Medicine, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1167","published-online":{"date-parts":[[2022,10,3]]},"reference":[{"key":"2023053113303419700_B1","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc22-Sint","article-title":"Standards of Medical Care in Diabetes\u20142022","volume":"45","author":"American Diabetes Association","year":"2022","journal-title":"Diabetes Care"},{"key":"2023053113303419700_B2","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2022.06.008","article-title":"KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease","volume":"102","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group","year":"2022","journal-title":"Kidney Int"},{"key":"2023053113303419700_B3","unstructured":"International Diabetes Federation\n          . Diabetes facts & figures. Accessed 1 October 2020. Available from https:\/\/idf.org\/aboutdiabetes\/what-is-diabetes\/facts-figures.html"},{"key":"2023053113303419700_B4","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"2023053113303419700_B5","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/S0140-6736(17)30788-2","article-title":"Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy","volume":"390","author":"Levin","year":"2017","journal-title":"Lancet"},{"key":"2023053113303419700_B6","volume-title":"2020 USRDS Annual Data Report: Epidemiology of Kidney Disease in the United States","author":"United States Renal Data System","year":"2020"},{"key":"2023053113303419700_B7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1681\/ASN.2012070718","article-title":"Kidney disease and increased mortality risk in type 2 diabetes","volume":"24","author":"Afkarian","year":"2013","journal-title":"J Am Soc Nephrol"},{"key":"2023053113303419700_B8","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1016\/S0140-6736(12)61350-6","article-title":"Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis","volume":"380","author":"Fox","year":"2012","journal-title":"Lancet"},{"key":"2023053113303419700_B9","volume-title":"National Diabetes Statistics Report, 2020","author":"Centers for Disease Control and Prevention","year":"2020"},{"key":"2023053113303419700_B10","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1053\/j.ajkd.2020.01.007","article-title":"CKD awareness among US adults by future risk of kidney failure","volume":"76","author":"Chu","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2023053113303419700_B11","doi-asserted-by":"crossref","first-page":"e216139","DOI":"10.1001\/jamanetworkopen.2021.6139","article-title":"Association of race\/ethnicity, gender, and socioeconomic status with sodium-glucose cotransporter 2 inhibitor use among patients with diabetes in the US","volume":"4","author":"Eberly","year":"2021","journal-title":"JAMA Netw Open"},{"key":"2023053113303419700_B12","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/1753-0407.12524","article-title":"American Diabetes Association Standards of Medical Care in Diabetes 2017","volume":"9","author":"Marathe","year":"2017","journal-title":"J Diabetes"},{"key":"2023053113303419700_B13","doi-asserted-by":"crossref","first-page":"108072","DOI":"10.1016\/j.diabres.2020.108072","article-title":"Global and regional estimates and projections of diabetes-related health expenditure: results from the International Diabetes Federation Diabetes Atlas, 9th edition","volume":"162","author":"Williams","year":"2020","journal-title":"Diabetes Res Clin Pract"},{"key":"2023053113303419700_B14","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.2337\/dc20-0072","article-title":"Health care costs associated with macrovascular, microvascular, and metabolic complications of type 2 diabetes across time: estimates from a population-based cohort of more than 0.8 million individuals with up to 15 years of follow-up","volume":"43","author":"Chen","year":"2020","journal-title":"Diabetes Care"},{"key":"2023053113303419700_B15","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.2337\/dc19-2137","article-title":"The impact of cardiovascular disease and chronic kidney disease on life expectancy and direct medical cost in a 10-year diabetes cohort study","volume":"43","author":"Wan","year":"2020","journal-title":"Diabetes Care"},{"key":"2023053113303419700_B16","doi-asserted-by":"crossref","first-page":"825","DOI":"10.7326\/0003-4819-158-11-201306040-00007","article-title":"Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline","volume":"158","author":"Stevens","year":"2013","journal-title":"Ann Intern Med"},{"key":"2023053113303419700_B17","doi-asserted-by":"crossref","first-page":"S175","DOI":"10.2337\/dc22-S011","article-title":"11. Chronic kidney disease and risk management: Standards of Medical Care in Diabetes\u20142022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"2023053113303419700_B18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.kint.2020.10.012","article-title":"The case for early identification and intervention of chronic kidney disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference","volume":"99","author":"Shlipak","year":"2021","journal-title":"Kidney Int"},{"key":"2023053113303419700_B19","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.2337\/dc20-2715","article-title":"Chronic kidney disease testing among primary care patients with type 2 diabetes across 24 U.S. health care organizations","volume":"44","author":"Stempniewicz","year":"2021","journal-title":"Diabetes Care"},{"key":"2023053113303419700_B20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1053\/j.ajkd.2021.08.003","article-title":"A unifying approach for GFR estimation: recommendations of the NKF-ASN Task Force on reassessing the inclusion of race in diagnosing kidney disease","volume":"79","author":"Delgado","year":"2022","journal-title":"Am J Kidney Dis"},{"key":"2023053113303419700_B21","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1038\/ki.2013.500","article-title":"The accuracy of predicting cardiovascular death based on one compared to several albuminuria values","volume":"85","author":"Hatlen","year":"2014","journal-title":"Kidney Int"},{"key":"2023053113303419700_B22","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1056\/NEJMoa2102953","article-title":"New creatinine- and cystatin C-based equations to estimate GFR without race","volume":"385","author":"Inker","year":"2021","journal-title":"N Engl J Med"},{"key":"2023053113303419700_B23","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/jama.2019.14745","article-title":"Chronic kidney disease diagnosis and management: a review","volume":"322","author":"Chen","year":"2019","journal-title":"JAMA"},{"key":"2023053113303419700_B24","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1056\/NEJMoa2103753","article-title":"Race, genetic ancestry, and estimating kidney function in CKD","volume":"385","author":"Hsu","year":"2021","journal-title":"N Engl J Med"},{"key":"2023053113303419700_B25","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann Intern Med"},{"key":"2023053113303419700_B26","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","author":"Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group","year":"2013","journal-title":"Kidney Int"},{"key":"2023053113303419700_B27","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1053\/j.ajkd.2006.12.005","article-title":"KDOQI clinical practice guidelines and clinical practice recommendations for diabetes and chronic kidney disease","volume":"49","author":"KDOQI","year":"2007","journal-title":"Am J Kidney Dis"},{"key":"2023053113303419700_B28","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.kint.2019.09.020","article-title":"Rationale and design of the Transformative Research in Diabetic Nephropathy\u00a0(TRIDENT) Study","volume":"97","author":"Townsend","year":"2020","journal-title":"Kidney Int"},{"key":"2023053113303419700_B29","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.kint.2020.08.039","article-title":"Rationale and design of the Kidney Precision Medicine Project","volume":"99","author":"de Boer","year":"2021","journal-title":"Kidney Int"},{"key":"2023053113303419700_B30","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.2337\/dci18-0033","article-title":"Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)","volume":"41","author":"Davies","year":"2018","journal-title":"Diabetes Care"},{"key":"2023053113303419700_B31","doi-asserted-by":"crossref","first-page":"S60","DOI":"10.2337\/dc22-S005","article-title":"5. Facilitating behavior change and well-being to improve health outcomes: Standards of Medical Care in Diabetes\u20142022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"2023053113303419700_B32","doi-asserted-by":"crossref","first-page":"660","DOI":"10.2215\/CJN.10270620","article-title":"Integrating patient priorities with science by community engagement in the Kidney Precision Medicine Project","volume":"16","author":"Tuttle","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023053113303419700_B33","doi-asserted-by":"crossref","first-page":"991","DOI":"10.2215\/CJN.18191120","article-title":"The patient voice in health care decision making: the perspective of people living with diabetes and CKD","volume":"16","author":"Sadusky","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023053113303419700_B34","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.2337\/dc22-S004","article-title":"4. Comprehensive medical evaluation and assessment of comorbidities: Standards of Medical Care in Diabetes\u20142022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"2023053113303419700_B35","volume-title":"Protein and Amino Acid Requirements in Human Nutrition","author":"Joint WHO\/FAO\/UNU Expert Consultation","year":"2007"},{"key":"2023053113303419700_B36","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1053\/j.ajkd.2020.05.006","article-title":"KDOQI clinical practice guideline for nutrition in CKD: 2020 update","volume":"76","author":"Ikizler","year":"2020","journal-title":"Am J Kidney Dis"},{"key":"2023053113303419700_B37","doi-asserted-by":"crossref","first-page":"S97","DOI":"10.2337\/dc22-S007","article-title":"7. Diabetes technology: Standards of Medical Care in Diabetes\u20142022","volume":"45","author":"Draznin","year":"2022","journal-title":"Diabetes Care"},{"key":"2023053113303419700_B38","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.2337\/dci17-0026","article-title":"Diabetes and hypertension: a position statement by the American Diabetes Association","volume":"40","author":"de Boer","year":"2017","journal-title":"Diabetes Care"},{"key":"2023053113303419700_B39","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","article-title":"KDIGO 2021 clinical practice guideline for the management of blood pressure in chronic kidney disease","volume":"99","author":"Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group","year":"2021","journal-title":"Kidney Int"},{"key":"2023053113303419700_B40","doi-asserted-by":"crossref","first-page":"S144","DOI":"10.2337\/dc22-S010","article-title":"10. Cardiovascular disease and risk management: Standards of Medical Care in Diabetes\u20142022","volume":"45","author":"American Diabetes Association Professional Practice Committee","year":"2022","journal-title":"Diabetes Care"},{"key":"2023053113303419700_B41","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1001\/jama.2018.0642","article-title":"Individualizing blood pressure targets for people with diabetes and hypertension: comparing the ADA and the ACC\/AHA recommendations","volume":"319","author":"de Boer","year":"2018","journal-title":"JAMA"},{"key":"2023053113303419700_B42","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N Engl J Med"},{"key":"2023053113303419700_B43","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1046\/j.1523-1755.2003.00885.x","article-title":"The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study","volume":"63","author":"Keane","year":"2003","journal-title":"Kidney Int"},{"key":"2023053113303419700_B44","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N Engl J Med"},{"key":"2023053113303419700_B45","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1161\/HYPERTENSIONAHA.120.16667","article-title":"Comparative first-line effectiveness and safety of ACE (angiotensin-converting enzyme) inhibitors and angiotensin receptor blockers: s multinational cohort study","volume":"78","author":"Chen","year":"2021","journal-title":"Hypertension"},{"key":"2023053113303419700_B46","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"KDIGO clinical practice guideline for lipid management in CKD: summary of recommendation statements and clinical approach to the patient","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int"},{"key":"2023053113303419700_B47","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.ahj.2010.08.012","article-title":"Study of Heart and Renal Protection (SHARP): randomized trial to assess the effects of lowering low-density lipoprotein cholesterol among 9,438 patients with chronic kidney disease","volume":"160","author":"Sharp Collaborative Group","year":"2010","journal-title":"Am Heart J"},{"key":"2023053113303419700_B48","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/S0140-6736(11)60739-3","article-title":"The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial","volume":"377","author":"Baigent","year":"2011","journal-title":"Lancet"},{"key":"2023053113303419700_B49","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1056\/NEJMoa0810177","article-title":"Rosuvastatin and cardiovascular events in patients undergoing hemodialysis","volume":"360","author":"Fellstr\u00f6m","year":"2009","journal-title":"N Engl J Med"},{"key":"2023053113303419700_B50","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1159\/000080241","article-title":"Randomized controlled trial on the efficacy and safety of atorvastatin in patients with type 2 diabetes on hemodialysis (4D study): demographic and baseline characteristics","volume":"27","author":"Wanner","year":"2004","journal-title":"Kidney Blood Press Res"},{"key":"2023053113303419700_B51","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.2337\/dc22-Sint","article-title":"Introduction: Standards of Medical Care in Diabetes\u20142022","volume":"45","author":"American Diabetes Association","year":"2022","journal-title":"Diabetes Care"},{"key":"2023053113303419700_B52","unstructured":"Glucophage [package insert]\n          . Princeton, NJ, Bristol-Myers Squibb Company, 2018. Accessed 31 March 2022. Available from https:\/\/packageinserts.bms.com\/pi\/pi_glucophage.pdf"},{"key":"2023053113303419700_B53","doi-asserted-by":"crossref","first-page":"2668","DOI":"10.1001\/jama.2014.15298","article-title":"Metformin in patients with type 2 diabetes and kidney disease: a systematic review","volume":"312","author":"Inzucchi","year":"2014","journal-title":"JAMA"},{"key":"2023053113303419700_B54","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1056\/NEJMoa2024816","article-title":"Dapagliflozin in patients with chronic kidney disease","volume":"383","author":"Heerspink","year":"2020","journal-title":"N Engl J Med"},{"key":"2023053113303419700_B55","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med"},{"key":"2023053113303419700_B56","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/S2213-8587(19)30256-6","article-title":"SGLT2 inhibitors for the prevention of kidney failure in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"7","author":"Neuen","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023053113303419700_B57","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1056\/NEJMoa2107038","article-title":"Empagliflozin in heart failure with a preserved ejection fraction","volume":"385","author":"Anker","year":"2021","journal-title":"N Engl J Med"},{"key":"2023053113303419700_B58","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1056\/NEJMoa2022190","article-title":"Cardiovascular and renal outcomes with empagliflozin in heart failure","volume":"383","author":"Packer","year":"2020","journal-title":"N Engl J Med"},{"key":"2023053113303419700_B59","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.2215\/CJN.10140620","article-title":"Effects of canagliflozin in patients with baseline eGFR &lt;30 ml\/min per 1.73 m2: subgroup analysis of the randomized CREDENCE trial","volume":"15","author":"Bakris","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023053113303419700_B60","doi-asserted-by":"crossref","first-page":"2352","DOI":"10.1681\/ASN.2021020167","article-title":"Effects of dapagliflozin in stage 4 chronic kidney disease","volume":"32","author":"Chertow","year":"2021","journal-title":"J Am Soc Nephrol"},{"key":"2023053113303419700_B61","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1093\/ehjcvp\/pvac001","article-title":"SGLT-2 inhibitors and cardiovascular outcomes in patients with and without a history of heart failure: a systematic review and meta-analysis","volume":"8","author":"Razuk","year":"2022","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"key":"2023053113303419700_B62","doi-asserted-by":"crossref","first-page":"101163","DOI":"10.1016\/j.eclinm.2021.101163","article-title":"Net effects of sodium-glucose co-transporter-2 inhibition in different patient groups: a meta-analysis of large placebo-controlled randomized trials","volume":"41","author":"Staplin","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2023053113303419700_B63","unstructured":"Boehringer Ingelheim\n          . Jardiance (empagliflozin) Phase III EMPA-KIDNEY trial will stop early due to clear positive efficacy in people with chronic kidney disease, 2022. Accessed 16 March 2022. Available from https:\/\/www.boehringer-ingelheim.com\/human-health\/metabolic-diseases\/early-stop-chronic-kidney-disease-trial-efficacy"},{"key":"2023053113303419700_B64","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2215\/CJN.18881220","article-title":"SGLT2 inhibitors in diabetic kidney disease","volume":"16","author":"Zoungas","year":"2021","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023053113303419700_B65","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.3389\/fphar.2019.01066","article-title":"Appraisal of non-cardiovascular safety for sodium-glucose co-transporter 2 inhibitors: a systematic review and meta-analysis of placebo-controlled randomized clinical trials","volume":"10","author":"Shi","year":"2019","journal-title":"Front Pharmacol"},{"key":"2023053113303419700_B66","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2337\/dbi20-0040","article-title":"SGLT2 inhibition for CKD and cardiovascular disease in type 2 diabetes: report of a scientific workshop sponsored by the National Kidney Foundation","volume":"70","author":"Tuttle","year":"2021","journal-title":"Diabetes"},{"key":"2023053113303419700_B67","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(19)31149-3","article-title":"Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial","volume":"394","author":"Gerstein","year":"2019","journal-title":"Lancet"},{"key":"2023053113303419700_B68","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/S0140-6736(18)32261-X","article-title":"Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial","volume":"392","author":"Hernandez","year":"2018","journal-title":"Lancet"},{"key":"2023053113303419700_B69","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.1161\/CIRCULATIONAHA.118.036418","article-title":"Effects of liraglutide versus placebo on cardiovascular events in patients with type 2 diabetes mellitus and chronic kidney disease","volume":"138","author":"Mann","year":"2018","journal-title":"Circulation"},{"key":"2023053113303419700_B70","doi-asserted-by":"crossref","first-page":"1834","DOI":"10.1056\/NEJMoa1607141","article-title":"Semaglutide and cardiovascular outcomes in patients with type 2 diabetes","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"2023053113303419700_B71","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/S2213-8587(21)00203-5","article-title":"Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials","volume":"9","author":"Sattar","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023053113303419700_B72","doi-asserted-by":"crossref","first-page":"446","DOI":"10.2337\/dc19-1065","article-title":"Microvascular and cardiovascular outcomes according to renal function in patients treated with once-weekly exenatide: insights from the EXSCEL trial","volume":"43","author":"Bethel","year":"2020","journal-title":"Diabetes Care"},{"key":"2023053113303419700_B73","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1056\/NEJMoa2108269","article-title":"Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes","volume":"385","author":"Gerstein","year":"2021","journal-title":"N Engl J Med"},{"key":"2023053113303419700_B74","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.1056\/NEJMoa1612917","article-title":"Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes","volume":"377","author":"Holman","year":"2017","journal-title":"N Engl J Med"},{"key":"2023053113303419700_B75","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1056\/NEJMoa1616011","article-title":"Liraglutide and renal outcomes in type 2 diabetes","volume":"377","author":"Mann","year":"2017","journal-title":"N Engl J Med"},{"key":"2023053113303419700_B76","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1056\/NEJMoa1509225","article-title":"Lixisenatide in patients with type 2 diabetes and acute coronary syndrome","volume":"373","author":"Pfeffer","year":"2015","journal-title":"N Engl J Med"},{"key":"2023053113303419700_B77","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S2213-8587(18)30104-9","article-title":"Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial","volume":"6","author":"Tuttle","year":"2018","journal-title":"Lancet Diabetes Endocrinol"},{"key":"2023053113303419700_B78","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.disamonth.2009.12.009","article-title":"Optimizing insulin therapy in patients with type 1 and type 2 diabetes mellitus: optimal dosing and timing in the outpatient setting","volume":"56","author":"Hahr","year":"2010","journal-title":"Dis Mon"},{"key":"2023053113303419700_B79","doi-asserted-by":"crossref","first-page":"363","DOI":"10.2337\/dc15-0858","article-title":"Severe hypoglycemia requiring medical intervention in a large cohort of adults with diabetes receiving care in U.S. integrated health care delivery systems: 2005\u20132011","volume":"39","author":"Pathak","year":"2016","journal-title":"Diabetes Care"},{"key":"2023053113303419700_B80","doi-asserted-by":"crossref","first-page":"3275","DOI":"10.1016\/j.transproceed.2019.05.023","article-title":"Use of empagliflozin in recipients of kidney transplant: a report of 8 cases","volume":"51","author":"Attallah","year":"2019","journal-title":"Transplant Proc"},{"key":"2023053113303419700_B81","doi-asserted-by":"crossref","first-page":"e450","DOI":"10.1097\/TXD.0000000000000885","article-title":"Efficacy and safety of empagliflozin in the management of diabetes mellitus in heart transplant recipients","volume":"5","author":"Cehic","year":"2019","journal-title":"Transplant Direct"},{"key":"2023053113303419700_B82","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2337\/dc19-0093","article-title":"Efficacy and safety of empagliflozin in renal transplant recipients with posttransplant diabetes mellitus","volume":"42","author":"Halden","year":"2019","journal-title":"Diabetes Care"},{"key":"2023053113303419700_B83","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1159\/000501854","article-title":"Sodium-glucose cotransporter 2 (SGLT2) inhibition in kidney transplant recipients with diabetes mellitus","volume":"44","author":"Mahling","year":"2019","journal-title":"Kidney Blood Press Res"},{"key":"2023053113303419700_B84","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/ajt.15223","article-title":"Empagliflozin in posttransplantation diabetes mellitus: a prospective, interventional pilot study on glucose metabolism, fluid volume, and patient safety","volume":"19","author":"Schwaiger","year":"2019","journal-title":"Am J Transplant"},{"key":"2023053113303419700_B85","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.2215\/CJN.06870520","article-title":"Esaxerenone (CS-3150) in patients with type 2 diabetes and microalbuminuria (ESAX-DN): phase 3 randomized controlled clinical trial","volume":"15","author":"Ito","year":"2020","journal-title":"Clin J Am Soc Nephrol"},{"key":"2023053113303419700_B86","doi-asserted-by":"crossref","first-page":"2219","DOI":"10.1056\/NEJMoa2025845","article-title":"Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes","volume":"383","author":"Bakris","year":"2020","journal-title":"N Engl J Med"},{"key":"2023053113303419700_B87","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1056\/NEJMoa2110956","article-title":"Cardiovascular events with finerenone in kidney disease and type 2 diabetes","volume":"385","author":"Pitt","year":"2021","journal-title":"N Engl J Med"},{"key":"2023053113303419700_B88","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1093\/eurheartj\/ehab777","article-title":"Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis","volume":"43","author":"Agarwal","year":"2022","journal-title":"Eur Heart J"},{"key":"2023053113303419700_B89","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1681\/ASN.2021070942","article-title":"Hyperkalemia risk with finerenone: results from the FIDELIO-DKD trial","volume":"33","author":"Agarwal","year":"2022","journal-title":"J Am Soc Nephrol"}],"container-title":["Diabetes Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/45\/12\/3075\/716256\/dci220027.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/diabetesjournals.org\/care\/article-pdf\/45\/12\/3075\/716256\/dci220027.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,31]],"date-time":"2023-05-31T09:31:27Z","timestamp":1685525487000},"score":1,"resource":{"primary":{"URL":"https:\/\/diabetesjournals.org\/care\/article\/45\/12\/3075\/147614\/Diabetes-Management-in-Chronic-Kidney-Disease-A"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,3]]},"references-count":89,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,10,3]]},"published-print":{"date-parts":[[2022,12,1]]}},"URL":"https:\/\/doi.org\/10.2337\/dci22-0027","relation":{"has-preprint":[{"id-type":"doi","id":"10.2337\/figshare.20272404","asserted-by":"object"},{"id-type":"doi","id":"10.2337\/figshare.20272404.v1","asserted-by":"object"}]},"ISSN":["0149-5992","1935-5548"],"issn-type":[{"value":"0149-5992","type":"print"},{"value":"1935-5548","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,3]]}}}